**Company Overview**

Novogen (ASX:NRT, NASDAQ:NVGN) differentiates itself in the marketspace from all other stem cell and cancer therapy biotechs. Why? Because our product will target the stem cell and the somatic cell in the one drug.

Novogen has an extensive program based around two propriety drug technologies targeting significant unmet clinical needs. The aim of both these platforms is to convert cancer and other degenerative diseases into non-lethal manageable conditions. Novogen’s pipeline of drug candidates does not just focus on the unmet need of one cancer, but the drug candidates potential **covers 90% of cancer types** thereby increasing the market size significantly. One of these drug technologies TRX-E-002-1 is the first single drug capable of killing both the stem (parent cell) and somatic (daughter) cell. Novogen believes that this is a game changing development that offers the first realistic prospect of eradicating the source of cancer cells, thereby delivery long term remission.

In November 2013, Novogen formed a joint venture company (CanTx Inc) with Yale University, being the only Australian Biotech company to have entered into a partnership with a US Ivy League University.

Novogen is Sydney based with an office in New Haven, Connecticut.

**Investment Highlights**

* World first technology capable of producing drugs that kill the stem and somatic cells in equal measure
* Global operations with offices in the US and Australia
* Multi billion dollar market opportunities
* Pipeline of unique and highly valued intellectual property portfolio
* Novogen has established strong partnerships with academic institutions and other for profit and not for profit companies in Australia, US and Europe.
* Clinical Trials commencing 2015
* XXX Patents

**Key Announcements 2014**

***November 2014***

* Cantrixil proves highly effective in pre-clinical test of refractory ovarian cancer – Confirmation Cantrixil, has passed its final pre-clinical test of efficacy as evidence of its potential to significantly improve the survival prospects of patients with late-stage ovarian cancer.

***October 2014***

* Studies confirm TRX-E-009-1, one of Novogen’s lead drug candidate compounds has the ability to kill paediatric brain cancer cells, clearing the way for the compound to come into the clinic as a potential treatment of childhood cancers.

***September 2014***

* ABC TV Interview with Dr Graham Kelly discussing the Novogen program

***August 2014***

* Announcement of funding provided by FSHD Global Research Foundation supporting a collaboration between Novogen and fellow Australian biotechnology company, Genea Biocells

***June 2014***

* Novogen and CanTx announce potency of Intra-Peritoneal Trx-1 confirmed against chemo-resistant ovarian cancer stem cells

***May 2014***

* Novogen identifies highly active drug candidates against prostate cancer extending Novogen’s pre-clinical program to include prostate as well as brain cancer.
* Novogen partners with the Children’s Oncology Drug Alliance to form a unique research and development alliance to facilitate development of trestments for children with cancer.
* Novogen and Genea Announce partnership to investigate promising new approach to neurodegenerative diseases

***March 2014***

* Novogen and CanTx confirm an important milestone with lead candidate drug Trx-1 demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cell